Developed and characterized by a team of dedicated scientists and clinicians, BriaVax™ is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line.
The mechanism of action of BriaVax™ is currently under investigation. We suspect that the expression of certain immunogenic peptides in BriaVax™ generates strong antibody and T-cell responses – which results in recognition and destruction of cancerous cells.
BriaVax™ is designed to secrete granulocyte/macrophage-colony stimulating factor (GM-CSF), an immune system activator. We believe that GM-CSF activates the T cells of the immune system to recognize the tumor cells as foreign, and eliminate them. To amplify the immune system activation of the cancer patients, we have combined BriaVax™ with other immune system activators including cyclophosphamide, and interferon-α, a cytokine. We believe this approach of simultaneous activation of the immune system via different immune-triggering pathways will improve the immune system response for recognizing and eliminating cancerous cells, and will ultimately enhance the clinical benefits of BriaVax™.
Using BriaCell’s novel technology platform and our strong R&D capabilities, we may have the opportunity to develop vaccine candidates for other cancer indications including prostate, ovarian, kidney, lung, and even brain.
To provide financial and development support, we are currently discussing the development of our vaccine candidates with potential collaborators and partners.